


United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/743,752	03/12/2001	Olga Bandman	PF-0559 USN	7326	
7:	590 06/18/2002				
Incyte Genomics Inc		EXAMINER			
3160 Porter Drive Palo Alto, CA 94304			WINKLER, ULRIKE		
			ART UNIT	PAPER NUMBER	
			1648		
			DATE MAILED: 06/18/2002	S	

Please find below and/or attached an Office communication concerning this application or proceeding.





Commissioner for Patents United States Patent and Trademark Office Washington, DC 20231

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO. EXAMINER	
			ART UNIT	PAPER
				5
			DATE MAILEE) .

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ulrike Winkler whose telephone number is (703) 308-8294. The examiner can normally be reached on M-F 9 a.m.- 5p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached at (703) 308-4027. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

JEFFREY STUCKER PRIMARY EXAMINER

	Application No.	Applicant(s)				
Notice to Comply	09/743,752	BANDMAN ET AL.				
Notice to Comply	Examiner	Art Unit				
	Ulrike Winkler, Ph.D.	1648				
NOTICE TO COMPLY WITH REQUIREMENT	S FOR PATENT APPLICAT	TIONS CONTA	AINING			
NUCLEOTIDE SEQUENCE AND/OR AMINO	ACID SEQUENCE DISCLO	SURES				
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).						
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):						
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).						
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).						
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."						
5. The computer readable form that has been filed vunreadable as indicated on the attached CRF Diske submitted as required by 37 C.F.R. 1.825(d).	with this application has been foun tte Problem Report. A Substitute	d to be damaged computer readab	l and/or le form must be			
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).						
☐ 7. Other:						
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF	c) copy of the "Sequence Listing".					
An initial or substitute paper copy of the "Sequence specification.	Listing", as well as an amendment	directing its entr	y into the			
A statement that the content of the paper and comp no new matter, as required by 37 C.F.R. 1.821(e) or 1.82	outer readable copies are the sam 21(f) or 1.821(g) or 1.825(b) or 1.8	e and, where app 25(d).	plicable, include			
For questions regarding compliance to these re	equirements, please contact:					
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212						

Patentln Software Program Support

Technical Assistance......703-287-0200 To Purchase Patentin Software.....703-306-2600 PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY